Fig. A1 Tumor growth in a small number of RECORD-1 patients was not well described by model 2 with E5 ≠ E10. These included: i-iv) resistant patients (n = 4); (v) 5 mg of everolimus had an equivalent effect to 10 mg of everolimus (n = 1); (vi) tumor shrinkage during placebo treatment, but progression due to nontarget lesions (n = 1); (vii) tumor growth at 10 mg everolimus is faster than tumor growth at 5 mg everolimus (n = 1). E5, treatment effect of everolimus 5 mg daily; E10, treatment effect of everolimus 10 mg daily; SLD, sum of the longest tumor diameters.
Format: DOC Size: 246KB Download file
This file can be viewed with: Microsoft Word Viewer
Stein et al. BMC Cancer 2012 12:311 doi:10.1186/1471-2407-12-311